The FDA approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 receptor agonist for chronic weight management, on April 1, 2026, according to the company's announcement. In clinical trials, adults taking the highest dose lost an average of 12.4 percent of body weight.
Newspaper Daily publishes information, not medical advice. The outlet reports on regulatory actions and research findings and does not provide diagnosis or treatment guidance.
How the pill differs from injections
Approved GLP-1 therapies for weight loss have largely been weekly injections, with one oral semaglutide product already on the market. Foundayo is a small-molecule pill that, per the company, can be taken at any time of day without food or water restrictions, a dosing profile no other approved GLP-1 weight-loss pill offers. The approval moved through the FDA's commissioner's national priority voucher program, which the agency uses to speed review of selected applications.
The drug is indicated for adults with obesity and for some adults with overweight who have weight-related medical conditions, alongside diet and exercise, the labeling states.
Related stories: FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol · FDA Approves First Oral Antiviral to Prevent COVID-19 After Exposure.
What this approval can and cannot show
Trial results reported by the manufacturer show substantial average weight loss, but averages conceal wide individual variation, and the trial populations may differ from patients seen in routine care. The approval does not establish how long weight is maintained, how the pill compares head-to-head with injectable GLP-1s, or whether it reduces heart attacks or other clinical events; those questions require dedicated outcome trials. Cost and insurance coverage also remain open issues that an approval does not settle.
When to talk to a clinician
Weight-management decisions should be made with a clinician who can review an individual's history, current medications, and thyroid and pancreatic risk factors. Patients taking the drug who develop severe abdominal pain or symptoms of allergic reaction are advised to seek medical attention, consistent with the warnings common to the GLP-1 class.
Market context
Foundayo becomes the second oral prescription option for chronic weight management in the United States, intensifying competition in a category that has been dominated by injectable products.